Search research articles
Contact Us
Filters
Showing results (381-390 of 491) with videos related to
Page
of 50
Sort By:
Blood
|
July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen, Ajay K Gopal, Scott E Smith, et al.
Biological Psychiatry
|
April 21, 2023
Identifying Neurophysiological Markers of Intermittent Theta Burst Stimulation in Treatment-Resistant Depression Using Transcranial Magnetic Stimulation-Electroencephalography
Rebecca Strafella, Davide Momi, Reza Zomorrodi, et al.
Neuroimage
|
June 19, 2026
Combined continuous theta burst transcranial ultrasound and magnetic stimulation for induction of cortical plasticity
Kai-Hsiang Stanley Chen, Yih-Chih Jacinta Kuo, Wei-Chih Yang, et al.
Neurobiology of Disease
|
December 22, 2023
Subthalamic and pallidal neurons are modulated during externally cued movements in Parkinson's disease
Stephanie Tran, Tjitske C Heida, Janne J A Heijs, et al.
Blood
|
December 24, 2014
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Ajay K Gopal, Robert Chen, Scott E Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2019
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Joseph M Tuscano, Emanual Maverakis, Susan Groshen, et al.
Blood
|
September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 23, 2024
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
Swetha Kambhampati Thiruvengadam, Matthew G Mei, Lu Chen, et al.
Neurosurgery
|
June 12, 2026
Beyond Skull Density Ratio for Magnetic Resonance‑Guided Focused Ultrasound: A Literature Review of the Alternatives
Vikram Arora, Amirpooya Sadeghi, Brian Lim, et al.
Leukemia & Lymphoma
|
December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
Ajay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Page
of 50
Search research articles
Search
Showing results (381-390 of 491) with videos related to
Sort By:
Page
of 50
Blood
|
July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen, Ajay K Gopal, Scott E Smith, et al.
Biological Psychiatry
|
April 21, 2023
Identifying Neurophysiological Markers of Intermittent Theta Burst Stimulation in Treatment-Resistant Depression Using Transcranial Magnetic Stimulation-Electroencephalography
Rebecca Strafella, Davide Momi, Reza Zomorrodi, et al.
Neuroimage
|
June 19, 2026
Combined continuous theta burst transcranial ultrasound and magnetic stimulation for induction of cortical plasticity
Kai-Hsiang Stanley Chen, Yih-Chih Jacinta Kuo, Wei-Chih Yang, et al.
Neurobiology of Disease
|
December 22, 2023
Subthalamic and pallidal neurons are modulated during externally cued movements in Parkinson's disease
Stephanie Tran, Tjitske C Heida, Janne J A Heijs, et al.
Blood
|
December 24, 2014
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Ajay K Gopal, Robert Chen, Scott E Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2019
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Joseph M Tuscano, Emanual Maverakis, Susan Groshen, et al.
Blood
|
September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 23, 2024
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
Swetha Kambhampati Thiruvengadam, Matthew G Mei, Lu Chen, et al.
Neurosurgery
|
June 12, 2026
Beyond Skull Density Ratio for Magnetic Resonance‑Guided Focused Ultrasound: A Literature Review of the Alternatives
Vikram Arora, Amirpooya Sadeghi, Brian Lim, et al.
Leukemia & Lymphoma
|
December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
Ajay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Page
of 50